Importance of determining serologic markers in patients with celiac disease

BACKGROUND: Coeliac disease is presently considered to be an autoimmune disorder. Basis for the diagnosis is the invasive histochemical examination of the intestinal biopsy. Pathologic changes are classified into three grades according to the villous atrophy. Due to the autoimmune process, the patients serum levels of the specific and nonspecific antibodies, more which easily accessible to investigation, are increase.

METHODS AND RESULTS: One hundred thirty six probands (32 with coeliakia, 72 with other gastrointestinal disorders and 32 healthy ones) were included into the study. The antiendomysial, antireticular and antigliadin antibodies were examined. Results were compared with the histological finding in the gut sample. The highest sensitivity was found for antigliadin IgA antibodies (81%) and antiendomysial antibodies (75%). High specificity of the reaction in healthy subjects as well as in those with other gastrointestinal disorders (up to 100%), was found for antiendomysial and antireticular antibodies.

CONCLUSIONS: The most appropriate screening test the diagnosis of coeliac disease, appears to be the examination of the antigliadin antibodies of the class IgA and that of antiendomysial antibodies. On the basis of serology, today's high rate of underdiagnosing the disease can be prevented. However, the tests cannot differentiate between different degrees of the histological damage of the gut.

Medienart:

Artikel

Erscheinungsjahr:

2002

Erschienen:

2002

Enthalten in:

Zur Gesamtaufnahme - volume:141

Enthalten in:

Casopis lekaru ceskych - 141(2002), 15 vom: 02. Aug., Seite 487-90

Sprache:

Slowakisch

Weiterer Titel:

Význam vysetrenia serologických markerov u pacientov s celiakiou

Beteiligte Personen:

Ilavská, A [VerfasserIn]
Paulovicová, E [VerfasserIn]
Mikulecký, M [VerfasserIn]

Themen:

9007-90-3
Autoantibodies
Biomarkers
English Abstract
Gliadin
Immunoglobulins
Journal Article
Reticulin

Anmerkungen:

Date Completed 01.10.2002

Date Revised 19.11.2015

published: Print

Citation Status MEDLINE

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM120850222